NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy
Chemical Engineering Journal · 2025-04 · 510 · 161733
DOI: 10.1016/j.cej.2025.161733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Engineering Journal, 2025-04. Verfasst von Lushuang Xu und 7 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hangzhou Normal University, Medical Science and Technology Project of Zhejiang Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- National Natural Science Foundation of China
- Hangzhou Normal University
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Xu, L., Chen, Q., Qian, Y., Wang, J., Wang, C., Fan, R., Shen, J., & Shen, Q. (2025). NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy. Chemical Engineering Journal, 510, 161733. https://doi.org/10.1016/j.cej.2025.161733
Vancouver
Xu L, Chen Q, Qian Y, Wang J, Wang C, Fan R, et al. NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy. Chemical Engineering Journal. 2025;510:161733. doi:10.1016/j.cej.2025.161733
BibTeX
@article{Xu2025,
author = {Xu, Lushuang and Chen, Qinyue and Qian, Yangwei and Wang, Jin and Wang, Chenxi and Fan, Rui and Shen, Jia-Wei and Shen, Qiying},
title = {NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy},
journal = {Chemical Engineering Journal},
year = {2025},
volume = {510},
pages = {161733},
doi = {10.1016/j.cej.2025.161733}
}
EUVIMED